Ticker

Issued patents provide intellectual property protection for clinical candidates, AP-SA02 and AP-PA02, until at least 2041 LOS ANGELES, Oct. 7, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of…

Armata Pharmaceuticals Inc. (AMEX:ARMP) shares are trading lower on Wednesday as traders digest additional non-dilutive funding tied to its lead bacteriophage program.

Initial Phase 3-focused funding to support advancement of AP-SA02 in complicated Staphylococcus aureus bacteremia New commitment is incremental to previously announced DoW funding and expands total non-dilutive support for the AP-SA02 program to $32.4 million LOS ANGELES, Sept. 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology…

Controlled manufacturing reproducibly maintains defined genetic diversity across AP-SA02 clinical drug product lots Oral presentation scheduled for today Monday, Sept. 21, 2026 at the 20 th International Symposium on Staphylococci and Staphylococcal Infections LOS ANGELES, Sept.

Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over available therapies Potentially accelerating the path to market for this innovative antibacterial treatment AP-SA02 now holds Breakthrough Therapy, Fast Track and QIDP designations, providing strong regulatory validation LOS ANGELES, Sept. 14,…